NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/14/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization598.82 mln
Float33.90 mln
Earnings Date10/29/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-4.2
Highly reliable
1-Year Forecast
8.68
Transformational upside
Relative Strength
97
/ 100
Top performer
Debt / Equity
1.12
Elevated leverage
ROE
-144
Deeply negative
Business Description
Autolus Therapeutics is a UK-based biopharmaceutical company focused on developing advanced T cell therapies to treat various cancers and autoimmune conditions. Its leading program, obecabtagene autoleucel, targets a protein called CD19 and is currently being tested in clinical trials for certain types of leukemia in both adults and children. The company has several other therapies in development aimed at treating conditions such as lymphoma, neuroblastoma, and multiple myeloma. Founded in 2014 and headquartered in London, Autolus operates across multiple international markets.
